AI assistant
Immuneering Corp — Director's Dealing 2021
Jul 30, 2021
32973_dirs_2021-07-29_0e49fc7c-e8b7-4542-bfad-fb90812e4d2c.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2021-07-29
Reporting Person: CARPENTER ROBERT J (Director)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Class A Common Stock | 606666 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option | $3.01 | 2029-12-15 | Class A Common Stock (111153) | Direct | |
| Series A Preferred Stock | $ | Class A Common Stock (94585) | Direct | ||
| Series B Preferred Stock | $ | Class A Common Stock (122588) | Direct |
Footnotes
F1: The option vests and becomes exercisable as to 25% of the underlying shares on December 16, 2020 and then in equal monthly installments over the subsequent three years, subject to Mr. Carpenter's continued service to the Issuer's board of directors through each applicable vesting date.
F2: Each share of the Issuer's preferred stock is convertible on a one-for-one basis into shares of the Issuer's Class A common stock in certain circumstances and has no expiration date. The preferred stock will automatically convert into Class A common stock immediately prior to the closing of the Issuer's initial public offering.